Orbimed Advisors SC 13D/A Adicet Bio / ORBIMED ADVISORS ownership change

 EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this amendment to Schedule 13D, dated September 18, 2020 (the “Schedule 13D”), with respect to the Shares of Adicet Bio, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13D.  Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein.  This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 18^th day of September, 2020.

OrbiMed Advisors LLC
By:	/s/ Jonathan T. Silverstein
	Title:	Member
OrbiMed Capital GP V LLC
By:	OrbiMed Advisors LLC its Managing Member
By:	/s/ Jonathan T. Silverstein
	Title:	Member of OrbiMed Advisors LLC
OrbiMed Capital GP VI LLC
By:	OrbiMed Advisors LLC its Managing Member
By:	/s/ Jonathan T. Silverstein
	Title:	Member of OrbiMed Advisors LLC
OrbiMed Israel GP Ltd.
By:	/s/ Jonathan T. Silverstein
	Title:	Director
OrbiMed Israel BioFund GP Limited Partnership
By:	OrbiMed Israel GP Ltd. its General Partner
By:	/s/ Jonathan T. Silverstein
	Title:	Director of OrbiMed Israel GP Ltd.

OrbiMed Advisors Israel II Limited
By:	/s/ Jonathan T. Silverstein
	Title:	Director
OrbiMed Israel GP II, L.P.
By:	OrbiMed Advisors Israel II Limited its General Partner
By:	/s/ Jonathan T. Silverstein
	Title:	Director of OrbiMed Advisors Israel II Limited